Tumour regression and ERCC1 nuclear protein expression predict clinical outcome in patients with gastro-oesophageal cancer treated with neoadjuvant chemotherapy

Khaleel Fareed(University of Nottingham), Srinivasan Madhusudan(Nottingham University Hospitals NHS Trust), Philip Kaye(Nottingham University Hospitals NHS Trust), Jaina M. Patel(Nottingham University Hospitals NHS Trust), Irshad Soomro, Dileep N. Lobo(Nottingham University Hospitals NHS Trust), Simon L. Parsons(Galapagos (Belgium)), Ahmad Al‐Attar(Nottingham University Hospitals NHS Trust)
British Journal of Cancer
May 1, 2010
10.1038/sj.bjc.6605686
Cited by 81

Related Papers

Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
|New England Journal of Medicine|2010|4.5k
Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial
|The Lancet|2022|664
Guidelines for Perioperative Care in Bariatric Surgery: Enhanced Recovery After Surgery (ERAS) Society Recommendations
|World Journal of Surgery|2016|607
Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial
|The Lancet Oncology|2013|605
Consensus Statements for Management of Barrett's Dysplasia and Early-Stage Esophageal Adenocarcinoma, Based on a Delphi Process
|Gastroenterology|2012|378